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We demonstrate here that a deletion of 14 amino acid residues directly C-terminal to the major homology region (MHR) of the HIV-1 capsid
(CA) in Gag–Pol markedly affects the incorporation of Gag–Pol into virions. The 14-amino acid deletion also significantly impaired virus
assembly. In agreement with previous reports, mutations at the very C-terminus of CA resulted in a remarkable reduction in virus production.
However, HIV-1 Gag–Pol precursors containing the C-terminal CA mutation were still capable of being incorporated into virions at a level of
about 50% that of the wild-type. These results suggest that the domain immediately C-terminal to the MHR is functionally involved in Gag–Gag
and Gag/Gag–Pol interaction, and this supports the notion that Gag or Gag–Pol mutants blocked in assembly into virus particles can be rescued
into virions provided they retain the domains that are able to interact with the Gag precursor. An HIV-1 Gag–Pol deletion mutant retaining a
minimal sequence consisting of the MHR and the adjacent CA-SP1 was efficiently incorporated into virions. Analysis by immunofluorescence
staining indicated that the subcellular localization patterns shown by the Gag–Pol mutants were not fully compatible with their efficiency in being
incorporated into virions, suggesting that the ability of Gag–Pol mutants to be incorporated into virions largely depends on their interactions with
the Gag precursor.
© 2005 Elsevier Inc. All rights reserved.Keywords: Human immunodeficiency virus; Gag assembly; Gag–Pol incorporation; Major homology region (MHR); CA-SP1Introduction
The gag gene of all retroviruses, including human
immunodeficiency virus (HIV), encodes the viral structural
protein Gag (Hunter, 1994; Swanstrom and Wills, 1997). In
HIV, Gag is synthesized as a polyprotein precursor, Pr55gag.
During or soon after virus budding, Pr55gag is cleaved by the
pol-encoded protease (PR) into several distinct products,
namely matrix (MA; p17), capsid (CA; p24), nucleocapsid
(NC; p7), and the C-terminal p6 domain (Freed, 1998;
Henderson et al., 1992; Kaplan et al., 1994; Leis et al., 1988;
Mervis et al., 1988; Swanstrom and Wills, 1997). In addition,
two small cleavage products termed SP1 and SP2 separate NC⁎ Corresponding author. Fax: +886 2 28742279.
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doi:10.1016/j.virol.2005.12.009from CA and from p6, respectively. The pol gene, which
partially overlaps with the gag gene, encodes PR, reverse
transcriptase (RT), RNase H, and intergrase (IN). Pol is
translated as a polyprotein precursor, Pr160gag–pol, by a −1
ribosomal frameshift mechanism (Jacks et al., 1988). Within
Pr160gag–pol, the p6gag is truncated and replaced by a transframe
polypeptide (TF) termed the p6* or p6pol domain (Partin et al.,
1990). The ribosomal frameshift event occurs at a frequency of
about 5–10%, resulting in expressionof Pr55gag andPr160gag–pol
at a ratio of between 20:1 and 10:1 (Jacks et al., 1988). The
maintenance of the lower expression level for Gag–Pol or Gag–
PR is critical for virus particle production, as Gag–Pol that is
overexpressed artificially can block or significantly reduce the
production of virus particles (Arrigo and Huffman, 1995;
Burstein et al., 1991; Chiu et al., 2002; Krausslich, 1991; Park
and Morrow, 1991; Wang et al., 2000). How the HIV-1 PR is
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unclear. It is thought that activation of HIV-1 PR is initiated or
promoted through the formation of Gag–Pol dimers. The fully
functional PR, normally as a homodimer, then cleaves the Gag–
Pol and Gag precursors to yield the mature gag and pol gene
products (Navia and McKeever, 1990). The PR-mediated virus
maturation process is not required for virus assembly and
budding, but is essential for virus infectivity (Chen et al., 1997;
Gottlinger et al., 1989;Kohl et al., 1988; Peng et al., 1989;Rose et
al., 1995).
For most retroviruses including HIV, expression of gag
alone is sufficient for virus particle assembly and budding.
Genetic studies of retroviral Gag have defined three major
domains; these are the membrane-binding domain (M),
interaction domain (I), and the late (L) domain, to which
specific functional roles in the process of virus assembly and
budding have been ascribed. In HIV-1 the L domain is
located in the C-terminal of p6gag, which contains a PT/SAP
motif required for efficient virus budding (Freed, 2002). The
HIV-1 M domain contains a myristic acid moiety and a
cluster of basic residues at the N-terminus of the MA region.
These are required for Gag membrane association and plasma
membrane targeting (Bryant and Ratner, 1990; Facke et al.,
1993; Ono and Freed, 1999; Ono et al., 2000; Pal et al.,
1990). The I domain within the NC facilitates virus assembly
by promoting Gag–Gag interactions (Derdowski et al., 2004;
Lee et al., 1999; Sandefur et al., 2000; Zhang et al., 1998).
Extensive genetic analyses have suggested that the C-terminal
domain of CA and the adjacent SP1 are critical for Gag
multimerization and virus assembly (Abdurahman et al.,
2004; Accola et al., 1998; Ganser-Pornillos et al., 2004; Liang
et al., 2002, 2003; Melamed et al., 2004; Morikawa et al.,
2000; Reicin et al., 1995; Scarlata and Carter, 2003; von
Schwedler et al., 2003; Wang et al., 1998). In vitro studies
have also suggested that the Gag oligomerization domain is
contained within the C-terminal CA sequence (Ganser-
Pornillos et al., 2004). It has been shown that HIV-1 gag
deletion mutants retaining the N-terminal myristylation signal
and the C-terminal Gag domain can still direct virus particle
assembly and budding (Accola et al., 2000; Borsetti et al.,
1998). This suggests that the C-terminal CA and the adjacent
SP1 and NC regions are the most important determinants of
Gag oligomerization and assembly.
HIV-1 Gag–Pol is generally thought to be incorporated into
virus particles via interactions with the assembling Gag, by
virtue of its N-terminal Gag domain. Genetic studies involving
coexpression of Gag–Pol deletion mutants with a Pr55gag-
expression plasmid have shown that the C-terminal domain of
Gag in Gag–Pol is the most important region for its
incorporation into virus particles (Chiu et al., 2002; Srinivasa-
kumar et al., 1995). It is conceivable that HIV-1 Gag–Pol
mutants lacking the gag coding sequence involved in Gag
oligomerization may be defective in incorporation into virions.
In this study, we identified a region immediately C-terminal to
the MHR that significantly affected both virus assembly and the
incorporation of Gag–Pol into virions. Additionally, we defined
a minimal sequence, consisting of the MHR and the adjacentCA-SP1 sequence that is capable of directing the incorporation
of Gag–Pol into virions.
Results
The level of incorporated pol gene products from the Gag–Pol
mutants did not reflect the efficiency of virus particle
processing by Gag–Pol mutants
To define which regions within the C-terminal gag
sequence of Pr160gag–pol are able to affect the incorporation
of Pr160gag–pol into virus particles, a series of Pr160gag–pol
mutant constructs with various deletions in the C-terminal
gag coding sequence was constructed. As illustrated in Fig. 1
and Table 1, constructs Δ310–323 and Δ322–338, respec-
tively, contain a deletion of 14 and 17 residues downstream of
the MHR domain. Δ339–365 has a deleted sequence
including the very last 25 C-terminal residues of the CA
domain and the first two residues of SP1; both Δ374–378
and Δ368–378 have the SP1 sequence partially or almost
deleted, respectively; Δ385–429 has the NC domain deleted.
As described previously, Δ16–429 has the gag coding
sequence almost deleted (Chiu et al., 2002). Further C-
terminal deletions extending to include the p6pol and/or the
PR domain yielded constructs Δ16-PR and Δ16-RT,
respectively. HIV-1 Gag–Pol lacking the MHR (Δ281–308),
or the N-terminal two-thirds of the gag coding sequence but
retaining the myristylation signal (Δ16–282), has been shown
to be capable of being incorporated into virions (Chiu et al.,
2002, 2004). These two mutations were included as controls
in this study. Double-mutation constructs were made by
introducing the Δ16–282 deletion into the above Gag–Pol
constructs, to give constructs Δ16–282/310–323, Δ16–282/
339–365, Δ16–282/368–378, Δ16–282/374–378, and Δ16–
282/385–429.
To test the effect of the deletion mutations on the
incorporation of Gag–Pol into virus particles, wt GPfs or each
of the GPfs mutants (except the PR-defective mutant Δ16-RT)
were cotransfected with the Pr55gag-expressing plasmid pGAG
into 293T cells. The ability of each of the Gag–Pol deletion
mutants to be incorporated into virus particles and to process
Gag particles was analyzed byWestern immunoblot. The results
shown in Fig. 2 suggest that all the Gag–Pol mutants except
Δ16–429 andΔ16-PR could be incorporated and could process
Gag particles, as the virus-associated mature p24gag could be
readily detected (lanes 2–7 and 11–16). The relatively lower
level of virus-associated RT observed with Δ16–429 and Δ16–
PR may reflect their severe defects in both virus particle
incorporation and processing. However, the level of virus-
associated RT shown by the mutants did not completely
correlate with the efficiency of their virus particle processing.
For example, the Δ16–282 and the double mutants derived
from it all showed a Gag processing profile similar to that of the
wt; however, Δ16–282 and Δ16–282/374–378 were able to
and the other three double mutants were unable to produce
substantial amounts of virus-associated RT (lanes 10–15). This
suggests that some of the Gag–Pol deletion mutations may have
Fig. 1. Schematic representations of HIV-1 Pr160gag–polmutants. Wild-type (WT) Gag protein domains, major homology region (MHR), and the pol-encoded p6*, PR,
and RT domains are indicated. All of the Gag–Pol mutants are derived from the plasmid GPfs, which were constructed by placing gag and pol in the same open reading
frame via a five-T nucleotide deletion in the overlap region of gag–pol. The numbers indicate the position of the amino acid residue of the HIV-1 Gag precursor, and are
used to denote each of the mutant constructs with either a linker insertion (asterisks) or a deletion mutation in the gag–pol coding sequence. The boundaries of the
deleted gag–pol sequences are indicated (solid lines and arrowheads). Mutations with deletion of the sequence from the Gag residue 16 to the N-terminus of the PR and
RT domain are designated as Δ16-PR and Δ16-RT, respectively. Dashed lines in the double mutant constructs indicate deleted regions. The sequences in the mutated
region are given in Table 1.
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incorporated Gag–Pol may well provide sufficient PR activity
for Gag processing.
HIV-1 Gag–Pol precursors lacking 14 amino acid residues
directly C-terminal to the MHR were not capable of being
incorporated into virions, while Gag–Pol precursors retaining
a minimal sequence consisting of the MHR and the adjacent
CA-SP1 were not blocked
Since both the level of virus particle production and the
process of Gag–Pol incorporation into virions can be influenced
by the PR activity expressed in parallel, it might be possible to
assess the level of virus-associated Gag–Pol more accurately if
PR was inactivated. To do so, a PR-defective mutation was
introduced into the wt and mutant GPfs constructs, and each of
the resultant PR-defective constructs was introduced by
cotransfection with pGAG at a DNA ratio of 1:1. The results
shown in Fig. 3 indicate that deletions of theMHR alone (Δ281–
308) or the sequence upstream of MHR (Δ16–282) had only
mild to moderate effects on Gag–Pol incorporation (Fig. 3A,
lane 2, and Fig. 3B, lane 3), which is consistent with a previous
report (Chiu et al., 2002). In contrast, a deletion of the 14
residues immediately C-terminal to the MHR (Δ310–323)
dramatically blocked Gag–Pol incorporation (Fig. 3A, lane 3).
The Δ322–338 deletion showed a moderate effect on Gag–Polincorporation (Fig. 3A, lane 10). Surprisingly, the Δ339–365
construct, with a deletion of the sequence shown to be crucial for
Gag oligomerization and virus assembly (Abdurahman et al.,
2004; Liang et al., 2003; Melamed et al., 2004; Ganser-Pornillos
et al., 2004) had only a moderate effect on the incorporation of
Gag–Pol into virions (lane 4). Constructs Δ368–378 (lane 5),
Δ374–378 (lane 6), and Δ385–429 (data not shown) all
produced a level of virus-associated Gag–Pol comparable to that
of wt, suggesting that mutations in the SP1 domain and the
adjacent NC domain of Gag–Pol have no major effects on the
incorporation of Gag–Pol into virions. Since the SP1 domain
and the CA–SP1 boundary sequence have both been shown to
play a crucial role in the process of Gag multimerization (Accola
et al., 1998; Liang et al., 2002, 2003; Guo et al., 2005), it would
therefore be of interest to test whether removal of the C-terminus
of CA and the adjacent SP1 from the HIV-1 Gag–Pol can affect
the incorporation of Gag–Pol into virus particles. The results
shown in Fig. 3C suggest that HIV-1Gag–Pol with a deletion of
the C-terminus and the adjacent SP1 (Δ339–378) could still be
incorporated into virions at a level of efficiency comparable to
that of wt.
Intriguingly, the double mutations Δ16–282/339–365 or
Δ16–282/368–378 significantly affected the incorporation of
Gag–Pol into virus particles, while Δ16–282/374–378 or
Δ16–282/385–429 had only modest effects on Gag–Pol
incorporation (Fig. 3B, lanes 5–8). Deletions of the coding
Table 1
Nucleotide sequence and altered amino acid residues at the juncture of mutated
regions
Constructs Sequences in mutated regions a
Δ16–282 nt 830–5′ cga tgg atc ctg gac ata 3′-nt 1644
R W I L D I
Δ281–308 nt 1622-5′ cct acc agg atc cga gct 3′-nt 1716
P T R I R A
in308 nt 1709-5′ caa gct cgg atc cga gct 3′-nt 1716
Q A R I R A
in321 nt 1745-5′ acc ttg tgg atc caa aat 3′-nt 1764
T L W I Q N
Δ310–323 nt 1709-5′ caa gct cgg atc caa aat 3′-nt 1764
Q A R I Q N
in338 nt1793-5′ gca ttg ggg atc cca gcg 3′-nt 1809
A L G I P A
Δ322–338 nt 1745-5′ acc ttg tgg atc cca gcg 3′-nt 1809
T L W I P A
in363 nt 1873-5′ gtt tgg atc caa gca atg 3′-nt 1890
V W I Q A M
Δ339–365 nt 1796-5′ ttg ggg atc caa gca atg 3′-nt 1890
L G I Q A M
Δ368–378 nt 1880-5′ gaa gca agg atc cag aga 3′-nt 1929
E A R I Q R
Δ339–378 nt 1793-5′ gca ttg ggg atc cag aga 3′-nt 1929
A L G I Q R
Δ374–378 nt 1901-5′ aat tca ggg atc cag aga 3′-nt 1929
N S G I Q R
Δ385–429 nt 1931-5′ aat ttt agg atc cag gct 3′-nt 2082
N F R I Q A
Δ16–429 nt 830-5′ cga tgg atc cag gct aat 3′-nt 2085
R W I Q A N
Δ16-PR nt 830-5′ cga tgg atc cac ttc cct 3′-nt 2255
R W I H F P
Δ16-RT nt 830-5′ cga tgg atc cat ttt ccc 3′-nt 2552
R W I H F P
a Inserted or altered amino acid residues are shown in boldface.
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RT) also significantly impaired the incorporation of Gag–Pol
(Fig. 3A, lanes 7–9). These results suggest that the MHR and
the adjacent C-terminal CA–SP1 sequence constitute a minimal
sequence required for efficient incorporation of Gag–Pol into
virions.
Indirect immunofluorescence studies of the Gag–Pol deletion
mutants
It is possible that the mutations may have affected Gag–Pol
transport and consequently influenced the incorporation of
Gag–Pol into virions. To test this possibility, 293T cells were
transfected with the wt GPfs or each of the mutant GPfs
constructs, and the intracellular location of Gag–Pol was
revealed by indirect immunofluorescence. As shown in Fig.
4A, the wt Gag–Pol precursor proteins were detected throughout
the cytoplasm of transfected cells and showed a heterogeneous
cytoplasmic staining and a clear perinuclear ring. Cells
expressing Δ281–308 (B), Δ310–323 (C),Δ322–338 (D),
Δ339–365 (E), Δ368–378 (F), Δ374–378 (G), Δ385–429
(H),Δ16–429 (I),Δ16–282 (L) or each of theΔ16–282 double
mutants (M–Q) showed a immunofluorescence staining pattern
hardly distinguishable from that of wt. In contrast, about 90% ofthe Δ16-PR or Δ16-RT transfectants displayed fluorescence
staining that was asymmetrically enriched for Gag–Pol in the
perinuclear area (Figs. 4J and K). This suggests that appropriate
cellular transport of Gag–Pol may have been impaired by the
twomutations and this may contribute in part to the severe defect
that these two mutants show during incorporation into virus
particles. However, most of the mutants were defective in
particle incorporation despite the fact that they demonstrated a
subcellular localization pattern similar to that of the wt (Table 2).
These results suggest that the ability of Gag–Pol mutants to be
incorporated into virions is largely dependent on whether the
mutations have affected the Gag/Gag–Pol interactions.
Mutations in the region immediately C-terminal to the MHR of
CA markedly reduce HIV-1 particle production
Since theΔ310–323 mutation in Gag–Pol markedly affected
the interaction of Gag–Pol with Pr55gag, it is quite possible that
this mutation may also affect Gag particle assembly. To test this
possibility, the deletion mutations Δ310–323, Δ322–338, and
Δ339–365, and the linker-insertion mutations in308, in321,
in338, and in363were introduced into the wt HIVgpt and each of
the resultant plasmids was expressed in 293Tcells. As expected,
theΔ310–323 mutation had the effect of reducing virus particle
production markedly (Fig. 5A, lane 5). Compared with the wt,
the level of pelletable Gag proteins released by Δ310–323 was
about 10 to 30% of the wt level (Fig. 5B). Virions released by the
mutant in321 were also greatly reduced to a level of about 20 to
40% compared to the wt. Mutants in363 and Δ339–365 were
both significantly impaired in virus assembly and release, which
is consistent with previous reports stating that mutations in the
C-terminus of CA result in disruption of HIV-1 virus assembly
and release (Abdurahman et al., 2004; Melamed et al., 2004).
Interestingly, a four-amino acid insertion at the C-terminus of
MHR (in308) or mutations (in338 andΔ322–338) located in the
region downstream of Δ310–323 but upstream of in363 had a
less detrimental effect on virus particle assembly and release
than Δ310–323 (Fig. 5A, lanes 3, 6, and 7). Notably, the PR-
mediated proteolytic processing of all the mutants except in308
was impaired to a certain degree, particularly in the case of
in321, Δ310–323, in363 and Δ339–365; all of them had the
Gag precursor representing the major species in the medium
samples (lanes 4, 5, 8, and 9). In addition to Pr55, p41, and p24/
25, some p24gag-associated products were detected, which may
have resulted from mutation-induced aberrant cleavage since
most of these products are not detectable when expressed in a
PR-negative version or in the presence of a HIV-1 protease
inhibitor (data not shown). Bands migrating slightly faster than
p24gag and at positions corresponding to CAwith small deletions
were detected in mutants Δ310–323, Δ322–338, and Δ339–
365. In contrast to the wt and other mutants, the mutant in363,
with a substitution of three amino acid residues at the extreme C-
terminus of CA, showed a relatively higher level of cell-
associated p25, presumably due to a block in the cleavage at CA-
SP1 (Fig. 5A, lane 17). Consistent with this finding, a mutant
with a substitution mutation at the last amino acid residue of
HIV-1 CA, and in which the CA-SP1 represents the major CA
Fig. 2. Processing and release of HIV-1Gag and Pol proteins from cells coexpressing Pr55gag and Pr160gag–pol. 293T cells were transfected with 10 μg of pGAG alone
or together with 1 μg of the designated plasmid. At 48 h posttransfection, culture supernatants and cells were collected and prepared for protein analysis as described in
Materials and methods. Supernatant samples corresponding to 50% of the total samples were fractionated by SDS-PAGE (10%) and electroblotted onto a nitrocellulose
filter. HIV-1Gag and Pol proteins were probed with a mouse anti-p24gag and a mouse anti-HIV-1-RT monoclonal antibody, respectively. The positions of the molecular
size markers are shown on the right and those of HIV-1Gag proteins Pr55, p41, p24/25, and RT proteins p66 and p51 are indicated on the left.
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2004).
Discussion
In this study, the ability of each of the HIV-1Gag–Pol
deletion mutants to be incorporated into virions was judged by
the level of virus-associated Gag–Pol protein. By coexpressing
the wt or each of the PR-intact Gag–Pol mutants with pGAG at
a DNA ratio of 10:1, mature virus-associated p24gag or RT
could be detected readily in the cotransfectant culture medium.
Exceptions to this rule were mutants Δ16–429 and Δ16-PR,
which showed a poor Gag processing profile. This suggests that
most Gag–Pol mutants could be incorporated into virions to a
certain degree. We found that the experimental results were
more reproducible and constant when the ratio of cotransfected
Gag and Gag–Pol expression plasmid DNA was kept at 10:1
rather than at 20:1. Without coexpression with Pr55gag, HIV-1
RT or Gag–Pol could not be detected in the medium samples,
suggesting that the Gag–Pol is virus-associated (data not
shown). The inability of both Δ16–429 and Δ16-PR to process
Gag particles may be due in part to defective PR activity, as the
level of intracellular p24gag produced by the two constructs was
also markedly lower than those of the other Gag–Pol mutants
(data not shown). This result is consistent with a previous
report, which found that removal of the sequence upstream of
the HIV-1 PR significantly affects PR activity (Zybarth and
Carter, 1995).
When expressed in a PR-defective version, HIV-1 Gag–Pol
precursors (Δ310–323) with 14 amino acid residues (CA178–191)
removed directly C-terminal to the MHR, were found to be
severely defective in particle incorporation. In contrast to
Δ310–323, both Δ339–365 and Δ281–308 (ΔMHR) showed
no detrimental effect on Gag–Pol incorporation, and significant
amounts of the two mutants were incorporated into virus
particles at a level over 50% of that of wt Gag–Pol (Fig. 3).Although one previous study has shown that removal of the
MHR in HIV-1 Gag–Pol significantly impairs the assembly of
Gag–Pol into virus particles (Srinivasakumar et al., 1995), our
previous and present studies have demonstrated that the Δ281–
308 construct has only mild to moderate effect on the
incorporation of Gag–Pol into virions (Chiu et al., 2002,
2004). Another group has reported that substitution mutations in
the HIV-1 MHR have no significant effect on Gag–Pol
incorporation (Mammano et al., 1994). It is unknown whether
the three foreign amino acid residues Arg–Ile–Arg inserted in
the deleted region of Δ281–308 have any positive effect on
Gag–Pol incorporation. Alternatively, this discrepancy may be
due to the different systems employed by the various research
groups.
It has previously been demonstrated that chimeric Gag–Pol
precursors in which the Moloney murine leukemia virus
(MLV) MHR and the adjacent C-terminal CA sequences were
replaced with their HIV-1 counterparts in a precise manner
could still be incorporated into HIV-1 particles, suggesting that
the MHR and adjacent CA in Gag–Pol is the region mainly
responsible for the interaction with Gag (Huang and Martin,
1997). In accord with this report, we have shown that the
Δ16–282 double mutations involving a removal of the C-
terminus of CA (Δ16–282/339–365) or SP1 (Δ16–282/368–
378) markedly inhibited the incorporation of Gag–Pol into
virions (Fig. 2, lanes 13 and 14, and Fig. 3B, lanes 5 and 6).
These HIV-1 Gag–Pol mutants contain large deletion muta-
tions and therefore we could not exclude the possibility that
the mutations may induce conformational changes in the
encoded Gag–Pol and as a consequence interfered with the
interactions between Gag–Pol and Gag. Nonetheless, we have
defined a minimal sequence consisting of the MHR and the
adjacent C-terminal CA-SP1 (Δ16–282/385–429) that can still
direct the incorporation of Gag–Pol into virus particles with an
efficiency over 70% of the wt level (Fig. 3B, lane 8). Our
results presented here suggest that retention of an intact C-
Fig. 3. Expression and incorporation of protease-defective (PR−) Gag–Pol deletion mutants into virus particles. 293T cells were transfected with 10 μg of pGAG alone
or together with 10 μg of the designated plasmids. All of the Gag–Pol constructs were expressed in a protease-inactivated version of GPfs. At 48 h posttransfection,
culture supernatants were collected, filtered, and pelleted through 20% sucrose cushions. Viral pellets and cell lysates were prepared for protein analysis as described in
Materials and methods. Membrane-bound HIV-1 proteins were probed with a mouse anti-HIV-RT monoclonal antibody or an HIV-positive human serum, followed by
a goat anti-mouse or anti-human HRP-conjugated antibody as secondary antibody, respectively. Positions of molecular size markers (Std.) and those of the HIV-
1Pr55gag and Pr160gag–pol are indicated. Levels of HIV-1Gag protein Pr55 and virus-associated Gag–Pol in each sample were quantified by scanning the density of the
various bands on the immunoblot. The ratios of total Gag–Pol versus Gag protein levels were calculated for each of the samples, and normalized to that of wt GPfs in
parallel experiments. Note that the immunoblots presented here were overexposed intentionally to allow visualization of the individual Pr160gag–pol mutants. Similar
results were observed in a number of repeat and independent experiments.
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incorporation when most of the N-terminal gag sequence
upstream of the MHR has been removed.With respect to the process of HIV-1 Gag assembly, the
capsid C-terminal domain (CTD) including the MHR and the
adjacent downstream sequence is thought to be crucial to Gag
Fig. 4. Detection of HIV-1Pr160gag–pol proteins in 293T cells by indirect immunofluorescence. 293T cells grown on coverslips were transfected with the PR-defective
version of wt GPfs (A) and mutants Δ281–308 (B), Δ310–323 (C), Δ322–338 (D), Δ339–365 (E), Δ368–378 (F), Δ374–378 (G), Δ385–429 (H), Δ16–429 (I),
Δ16–PR (J), Δ16–RT (K),Δ16–282 (L),Δ16–282/310–323 (M),Δ16–282/339–365 (N),Δ16–282/368–378 (O),Δ16–282/374–378 (P), Δ16–282/385–429(Q).
At 48 h posttransfection, cells were fixed and permeabilized for immunofluorescence assays as described in Materials and methods. The primary antibody was a mouse
anti-HIV-RT monoclonal antibody (1:500), and the secondary antibody was a 1:100 dilution of a rhodamine-conjugated rabbit anti-mouse antibody. Data shown
represent the most prevalent phenotypes. Mock-transfected 293T cells and cells not exposed to the primary antibody yielded no signals (data not shown). Scale bar in
panel A represents 10 μm.
90 A.-I. Chien et al. / Virology 348 (2006) 84–95oligomerization and virus assembly and has been referred to as
the dimerization domain. The dimerization domain contains
four putative α-helix followed by a structurally disordered
segment composed of the last 12 residues (Gamble et al.,
1997; Momany et al., 1996; Worthylake et al., 1999).
Crystallography studies have suggested the CTD (CA residues
146–231) dimerizes by parallel packing of the putative α-helix
2 (corresponding CA residues 179–192) across the dimer
interface (Gamble et al., 1997). Thus, the Δ310–323 mutant,
because of the removal of the CA residues 178–191, may have
a disrupted Gag–Gag interaction due to removal of most of the
α-helix sequence. In agreement with this observation,
substitution mutations in CA residues W184 and M185,
which have been removed in the mutant Δ310–323, have been
reported to significantly reduce production of virus particles
(von Schwedler et al., 2003). Crystallography studies of the
HIV-1 CA suggest that both W184 and M185 are buried in the
core of a symmetrical dimer interface, and alanine substitu-
tions at either position block CA dimerization in vitro (Gamble
et al., 1997; Ganser-Pornillos et al., 2004). In addition, wehave very recently found that an alanine substitution at Q179
or K182 abolished virus assembly (unpublished results). Thus,
the region immediately C-terminal to the MHR may be
functionally involved in the process of Gag multimerization.
The assembly defect caused by mutation Δ339–365 or in363
is not surprising, since a number of more recent studies have
shown that substitutions or deletions of the last 11 conserved
residues of CA, 354-VGGPGHLARVL-364, can cause a
drastic reduction in the level of virus production, possibly
due to impaired Gag multimerization (Abdurahman et al.,
2004; Liang et al., 2003; Melamed et al., 2004; von Schwedler
et al., 2003). That the Gag–Pol encoded by Δ339–365 is
capable of being rescued into Gag particles suggests that
mutations at the C terminus of CA do not disrupt the
interactions of Gag–Pol with Pr55gag to any great extent.
Thus, Gag or Gag–Pol mutants containing mutations blocking
virus assembly or Gag–Pol incorporation ought to still interact
with the wt Gag. In agreement with this proposal, HIV-1 Gag
or Gag–Pol carrying substitution mutations in the MHR show
severe impairment of virus assembly, but have been shown to
Table 2
Summary of the relative efficiency of Gag–Pol incorporation and the























a The ability of the Gag–Pol mutants to be incorporated into virus particles is
indicated: ++++, incorporation efficiency comparable to wt (≥80% of wt); +++,
efficiency about 50–70% of wt; ++, efficiency about 30–50% of wt; +,
efficiency about 10–20% of wt; −, efficiency below 10% of wt.
b ‘+++’ indicates over 90% of transfected 293T cells show fluorescence
staining asymmetrically enriched in the perinuclear area. ‘−’ Indicates a wild-
type Gag–Pol distribution pattern with a heterogeneous cytoplasmic staining
and a perinuclear ring; ‘ND’, not done.
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rescued into virus particles (Mammano et al., 1994). The
detrimental effect of the Δ310–323 mutation on both virus
assembly and Gag–Pol incorporation strongly suggests that the
domain immediately C-terminal to the MHR is required to
achieve efficient Gag/Gag or Gag/Gag–Pol interactions, which
are essential for virus assembly and for incorporation of Gag–
Pol into virions.
One recent study has demonstrated that HIV-1 Pol with a
V5 tag can be incorporated into virus particles at a efficiency
about 70% of that of wild-type Gag–Pol (Cen et al., 2004).
Our present and previous studies indicate that HIV-1 Gag–Pol
lacking the coding sequence upstream of the HIV-1 Pol or
p6pol can still be incorporated into virions, albeit at a
relatively lower efficiency (Fig. 3A, lanes 7 and 8). It is not
known whether the retained N-terminal fourteen MA residues
and the foreign residues inserted within the deleted region of
our Gag–Pol constructs have any effect on the entry of the
encoded Gag–Pol into virions. In the case of human foamy
virus, the pol gene is expressed as Pro–Pol from separately
spliced mRNA, and the Pol products are naturally incorpo-
rated into virions without the formation of Gag–Pol (Yu et al.,
1996). Moreover, free MLV Pol has been shown to be
capable of being incorporated into virions when MLV Pol and
MLV Gag are coexpressed from separate plasmids (Buchscha-
cher et al., 1999). These results suggest that retroviral Pol
may contain undefined signals that are capable of interacting
with Gag. Indeed, we have found that HIV-1 Pol truncated at
IN can be incorporated into virions more efficiently thanΔ16–429 (data not shown). Further studies are required to
test whether the HIV-1 RT can specifically interact with Gag.
Indirect immunofluorescence studies suggested thatΔ16-PR
and Δ16-RT were both localized asymmetrically in the
perinuclear area, which may account partly for their severe
defect in being packaged into virus particles. However, most of
the other mutants that were significantly defective in particle
incorporation showed a subcellular localization pattern similar
to that of wt. This suggests that cellular localization may not be
the primary determinant of Gag–Pol incorporation into virus
particles. At this point, we are unable to exclude the possibility
that there are minor effects of the mutations on the subcellular
localization of Gag–Pol as visualized by immunofluorescence
that may be masked when using the 293T cell overexpression
system. It has been demonstrated that the N-terminal myristyla-
tion signal required for both Gag plasma membrane targeting
and virus assembly can be removed from Gag–Pol without
impairing incorporation into virus particles (Chiu et al., 2002;
Park and Morrow, 1992; Smith et al., 1993). One recent study
has shown that the newly synthesized HIV-1 Gag–Pol
colocalizes very rapidly with Pr55gag into detergent-resistant
membrane (Halwani et al., 2003) suggesting that Gag may
mediate the transport of Gag–Pol via Gag/Gag–Pol interactions.
Collectively, these results suggest that the ability of each of the
Gag–Pol deletions to be incorporated depends largely on how
well the Gag–Pol mutant can interact with the coexpressed
Pr55gag. That bothΔ16-PR andΔ16-RT tend to localize around
perinuclear area suggests that removal of the transframe domain
p6pol could significantly affect the subcellular distribution of
Gag–Pol in the absence of the upstream Gag domain. It can be
speculated that the karyophilic properties of IN, which may be
exposed after the sequence upstream of PR has been removed,
contribute to the perinuclear localization pattern exhibited by




To construct the Gag–Pol deletion mutants, a series of
BamHI sites were introduced in-frame into HIV-1 proviral
positions at nt 836, 1751, 1803, 1884, 1907, 1923, 2076, and
2249 by PCR-mediated mutagenesis using HIVgpt (Page et
al., 1990) or an HIV-1 Gag–Pol frameshift mutant, GPfs
(Chiu et al., 2002) as template. BamHI-created mutations at nt
1751, 1803, and 1884 are designated in321, in338, and in363,
respectively, with the numbering referred to the Gag initiation
methionine residue. The construct in308 was engineered by
cutting viral DNA with HindIII (nt. 1712), filling-in and
inserting an 8-mer BamHI linker, which resulted in the
insertion of four amino acid residues (Ala–Arg–Ile–Arg).
DNA fragments spanning the above mutations were intro-
duced individually into plasmid pBRHIV831–5786, which
was constructed by cloning the HXB2 ClaI-831 to SalI-5786
fragment into pBR322 vector. Replacement of the fragment
ClaI-831 to BamHI-1751 with the fragment Cla1-831 to
Fig. 5. Expression and release of wt and mutant Gag proteins. (A) 293T cells were transfected with wt HIVgpt and mutant plasmids. Two days after transfection, the
cells and supernatants were collected for protein analysis as described in Materials and methods. Samples were fractionated by SDS-PAGE (10%) and then subjected to
immunoblot analysis with an anti-p24gag antibody as described in the legend to Fig. 2. The positions of molecular size markers (Std.) and those of HIV-1Gag proteins
Pr55, p41, and p24/25 are indicated. (B) Relative levels of virus particle production. Gag proteins from medium were quantified by scanning the mutant and wt p24gag-
associated band densities from the immunoblots. The total arbitrary densitometer units of each mutant were normalized to that of the wt in parallel experiments. Values
of the ratios indicate the relative levels of virus particles released. Error bars indicate the standard deviation.
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recombination among the other BamHI linker-inserted
mutants yielded deletion constructs Δ322–338, Δ339–365,
Δ368–378, Δ339–378, Δ374–378, Δ385–429 and Δ16-PR.
The ClaI-831 to SalI-5786 fragments containing each of the
deletion mutations were ligated into HIVgpt digested with
ClaI and SalI. Each of the mutant constructs was analyzed by
restriction enzyme digestion and confirmed by DNA
sequencing. The other Gag–Pol deletion constructs Δ16–
282, Δ281–308, Δ16–429, Δ16-RT, and HIV-1 Pr55gag-
expression plasmid pGAG have been described previously
(Chiu et al., 2002). The juncture sequences and altered amino
acid residue for the Gag and Gag–Pol constructs are shown in
Table 1.
Cell culture and transfection
293T cells were maintained in DMEM supplemented with
10% fetal calf serum. Confluent 293T cells were trypsinized,
split 1:10 and seeded onto 10-cm plates 24 h before
transfections. For each construct, 293T cells were transfected
with 20 μg of plasmid DNA by the calcium phosphateprecipitation method (Graham and van der Eb, 1973) with the
addition of 50 μm chloroquine to enhance transfection
efficiency. When the wild-type (wt) or mutant GPfs were
cotransfected with pGAG, 1 μg of each construct and 10 μg
of pGAG were used together with the addition of 9 μg
pBlueScript SK, to give a final 20 μg plasmid DNA. For
cotransfection of PR-defective (PR−) GPfs constructs with
pGAG, 10 μg of each construct and 10 μg of pGAG were
used. Culture media and cells were harvested for protein
analysis at 48 h posttransfection.
Western immunoblot analysis
Culture medium from transfected 293T cells was filtered
through 0.45-μm pore-size filters; this was followed by
centrifugation at 4 °C through 2 ml 20% sucrose in TSE
(10 mM Tris–HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA)
containing 0.1 mM phenylmethylsulfonyl fluoride (PMSF) for
40 min at 274,000×g (SW41 rotor at 40,000 rpm). Viral
pellets then were suspended in IPB (20 mM Tris–HCl, pH 7.5,
150 mM NaCl, 1 mM EDTA, 0.1% SDS, 0.5% sodium
deoxycholate, 1% Triton X-100, 0.02% sodium azide)
93A.-I. Chien et al. / Virology 348 (2006) 84–95containing 0.1 mM PMSF. The cells were rinsed with ice-cold
phosphate-buffered saline (PBS), scraped from the plates,
collected in 1 ml PBS and pelleted at 2500 rpm for 5 min. The
cell pellets were resuspended in 250 μl IPB containing 0.1
mM PMSF, and then subjected to microcentrifugation at 4 °C
for 15 min at 13,700×g (14,000 rpm) to remove cell debris.
Supernatant and cell samples were mixed with equal volumes
of 2× sample buffer (12.5 mM Tris–HCl, pH 6.8, 2% SDS,
20% glycerol, 0.25% bromophenol blue) and β-mercaptoetha-
nol (5%), and boiled for 5 min. The samples were subjected to
SDS-PAGE and electroblotted onto nitrocellulose membranes.
The membranes were blocked with 3% gelatin in Tris-buffered
saline containing 0.05% Tween 20 (TBST), followed by
incubation with the primary antibody in 1% gelatin-TBST for
1 h on a rocking platform at room temperature. The
membranes were then washed three times for 10 min each
with TBST, and rocked for 30 min with the secondary
antibody in 1% gelatin-TBST. The blots were again washed
three times in TBST for 10 min each, and the membrane-
bound antibody-conjugated enzyme activity was detected by
an enhanced chemiluminescence (ECL) detection system or by
a colorimetric method. For detection of HIV-1 Gag proteins,
we used anti-p24gag (a mouse hybridoma clone 183-H12-5C)
monoclonal antibody at a 1:5,000 dilution from ascites. To
detect HIV-1 RT or Gag–Pol deletion mutants, a mouse
monoclonal antibody against HIV-1 RT or an HIV-positive
human serum was used at 1:10,000 dilution as the primary
antibody. The secondary antibody was either alkaline
phosphatase conjugated horse anti-mouse IgG (Vector Labo-
ratories), HRP-conjugated goat anti-human antibody, or HRP-
conjugated rabbit anti-mouse antibody (Pierce). Procedures for
detection of alkaline phosphatase and HRP activity followed
the manufacturers' protocols.
Indirect immunofluorescence
The protocol for immunofluorescence was as previously
described (Wang et al., 1998). Briefly, confluent 293T cells
were split 1:80 and seeded onto coverslips 24 h before
transfection. Two days after transfection, the cells were fixed
at 4 °C for 20 min with ice-cold PBS containing 3.7%
formaldehyde. They were then washed once with PBS and
once with DMEM containing 10% heat-inactivated calf
serum (DMEM/calf serum) and permeabilized at room
temperature for 10 min in PBS containing 0.2% Triton X-
100. Samples were incubated with the primary antibody for 1
h and secondary antibody for 30 min. Following each
incubation, the samples were subjected to three 5- to 10-min
washes with DMEM/calf serum. The primary antibody was a
mouse anti-HIV-1 RT monoclonal antibody (Exalpha Biolo-
gicals Inc.) used at 1:500 dilution, and the secondary
antibody was a rabbit anti-mouse rhodamine-conjugated
antibody at 1:100 dilution (Cappel). After the last DMEM/
calf serum wash, the coverslips were washed three times with
PBS and mounted in 50% glycerol. Images were analyzed
and photographs taken using an Olympus FV300 confocal
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